EpiWatch
EpiWatch is a Baltimore-based digital health company that developed the first FDA-cleared seizure detection app for Apple Watch. It serves individuals with epilepsy experiencing tonic-clonic seizures, their caregivers, and prescribing physicians, using a $19.99/month subscription model in the US market.
- Company typePrivate
- Founded2015
- HeadquartersBaltimore, United States
- Headcount1–10
- GTM typeB2C
- OfferingSoftware
What EpiWatch does
EpiWatch, Inc. is a Baltimore-based digital health company that has developed the first and only FDA-cleared seizure detection application for Apple Watch. The product is a prescription-only mobile health application that runs passively on Apple Watch (watchOS 10+) paired with iPhone (iOS 17+), using proprietary machine learning algorithms to analyze continuous accelerometer and heart rate sensor data to detect tonic-clonic (grand mal) seizures in real time. When a seizure is detected, the system sends alerts to designated caregivers, shares GPS location, and supports rapid intervention to reduce risk of injury or Sudden Unexpected Death in Epilepsy (SUDEP). A March 2026 product update extended functionality to cellular-enabled Apple Watch devices, enabling standalone operation without an iPhone pairing.
The company monetizes through a $19.99/month subscription distributed exclusively via the Apple App Store, with HSA/FSA reimbursement available under most standard plans. Its go-to-market combines a self-serve App Store download with prescription validation, prescription-based physician activation, and emerging health system partnership channels pursued by CEO Teresa Prego. Primary customers are individuals with epilepsy experiencing tonic-clonic seizures, their caregivers and family members, and prescribing healthcare providers (neurologists, epileptologists, primary care physicians). EpiWatch is currently available only in the United States, with stated plans to expand to Android and additional devices. The company is privately held, was founded in 2015, has raised $415,000 in disclosed funding (March 2022), and operates with 1-10 employees. Its clinical evidence base was substantially strengthened in May 2026 with the publication of its Phase III trial in Neurology Open Access, the official journal of the American Academy of Neurology.
EpiWatch firmographics
Firmographics- Name
- EpiWatch
- Legal name
- EpiWatch, Inc.
- Website
- https://epiwatch.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- EpiWatch is a Baltimore-based digital health company that developed the first FDA-cleared seizure detection app for Apple Watch. It serves individuals with epilepsy experiencing tonic-clonic seizures, their caregivers, and prescribing physicians, using a $19.99/month subscription model in the US market.
- Ownership category
- akta.pro rank
EpiWatch industry classification
Industry- Product category
- Digital Health Software
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
- akta.pro secondary industry
- Wearable Medical Alert Devices (Pendants, Watches, Bands) (HSAHAHAI)
Keywords
Where EpiWatch is headquartered
LocationHeadquarters
- HQ city
- Baltimore
- HQ country
- United States
- HQ region
- North America
Markets served
EpiWatch business model
Business model- GTM type
- B2C
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Subscription (Apple App Store): Monthly subscription model at $19.99/month paid through Apple App Store. Subscription includes full EpiWatch services including seizure detection, caregiver alerts, cellular functionality, and GPS location sharing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Standard Monthly Subscription - $19.99/month |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels6 records
EpiWatch product offering
Product offeringCore offering
EpiWatch is a prescription-based mobile health application that runs on Apple Watch and iPhone to passively detect tonic-clonic (grand mal) seizures in real time and send alerts with GPS location to designated caregivers. It is the first and only FDA-cleared seizure detection app for Apple Watch, distributed via the Apple App Store on a $19.99/month subscription.
Product overview
EpiWatch offers a single unified product: the EpiWatch Seizure Detection App. This FDA-cleared mobile healthcare application is designed exclusively for Apple Watch (running watchOS 10 or higher) paired with iPhone (running iOS 17 or higher). The app provides continuous tonic-clonic seizure monitoring, real-time detection, and automatic caregiver alerting through the Apple Watch. The product is available by prescription for $19.99/month via the App Store.
Differentiator
Problem solved
Functional benefit
Products and services
- EpiWatch Seizure Detection App FDA-cleared, prescription-based mobile health application that runs passively on Apple Watch (watchOS 10+) paired with iPhone (iOS 17+) to detect tonic-clonic (grand mal) seizures in real time and send alerts with GPS location to designated caregivers. Distributed as a $19.99/month subscription through the Apple App Store; includes standalone cellular watch operation, Apple Family Sharing support, and HSA/FSA reimbursement eligibility. Target users are individuals with epilepsy and their family caregivers in the United States.
Quantifiable outcome
- Low rate of false alarms
- +1 more outcomes
Companies that use EpiWatch
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles2 records
EpiWatch technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
EpiWatch partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and minor.
- Anita Kaufmann Foundation (Purple Day)coreEpiWatch participates in Purple Day, a global epilepsy awareness initiative founded in 2008. The Anita Kaufmann Foundation serves as global sponsor of Purple Day. EpiWatch joins families, caregivers, clinicians, and advocacy groups to raise epilepsy awareness and demonstrate wearable monitoring technology.
- Epilepsy Foundation New EnglandcoreAdvocacy partner supporting epilepsy awareness and education. EpiWatch collaborates with this organization for community outreach and awareness initiatives.
- International League Against Epilepsy (ILAE)coreGlobal advocacy partner for epilepsy awareness and education initiatives.
- Danny Did FoundationminorAdvocacy partner focused on SUDEP awareness and seizure safety education. EpiWatch references the foundation's SUDEP educational resources on their website.
- Cameron Boyce FoundationminorAdvocacy partner supporting epilepsy awareness initiatives.
- Chelsea Hutchinson FoundationminorAdvocacy partner for epilepsy awareness and education.
- Cure EpilepsyminorResearch and advocacy organization focused on finding cures for epilepsy.
- Hidden TruthsminorAdvocacy partner for epilepsy awareness.
- Epilepsy Alliance AmericaminorAdvocacy partner supporting people with epilepsy and their families.
- Southwest Parents and Families of Children with Disabilities (SWPDC)minorAdvocacy partner for families of children with disabilities including epilepsy.
- PameminorAdvocacy partner for epilepsy awareness.
- Epilepsies Action NetworkminorAdvocacy partner focused on policy and awareness for epilepsy.
- ApplecoreEpiWatch is built exclusively for Apple Watch and iPhone devices. The app integrates with Apple Watch sensors for seizure detection, utilizes Apple Family Sharing for multi-user coordination, and distributes through the Apple App Store. Standalone watch functionality now works on cellular-enabled Apple Watch devices without requiring iPhone pairing.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
EpiWatch competitors and assessment
Company assessmentDirect peers
- Empatica: Empatica's Embrace and EpiMonitor are FDA-cleared wearable devices and apps for seizure detection, making it the most direct competitor to EpiWatch in the wearable seizure monitoring category with overlapping physician-prescribed, subscription-based GTM.
- Smart Monitor (Inspyre): Smart Monitor's Inspyre app detects tonic-clonic and other major motor seizures on smartwatches and sends alerts to caregivers, directly overlapping EpiWatch's value proposition, sensor-based detection approach, and Apple Watch compatibility.
- Brain Sentinel: Brain Sentinel's SPEAC System is an FDA-cleared surface electromyography device that detects tonic-clonic seizures and alerts caregivers. It targets the same clinical indication as EpiWatch's tonic-clonic detection with overlapping regulatory and physician-prescription GTM motion.
Emerging players
- Epitel: Epitel develops wireless, wearable EEG sensors (e.g., Epilog) for continuous seizure monitoring in ambulatory and at-home settings. It overlaps with EpiWatch's mission of continuous out-of-clinic seizure surveillance using a more invasive but data-rich sensor modality.
- Seer Medical: Seer Medical provides at-home video EEG monitoring and seizure detection services. While primarily a clinical monitoring service rather than a consumer wearable, it overlaps with EpiWatch's mission of capturing seizure events outside the clinic and informing treatment.
- Zeto: Zeto offers wireless EEG headset solutions for clinical and remote seizure monitoring. It overlaps with EpiWatch in the broader seizure-monitoring category but focuses on provider-grade EEG rather than consumer-friendly wearables.
Broad incumbents
- NeuroPace: NeuroPace's RNS System is an FDA-approved implantable neurostimulator that detects and responds to abnormal electrical patterns in the brain. While far more invasive than EpiWatch, it addresses the same underlying patient need (seizure monitoring/intervention) via a fundamentally different delivery model.
- Medtronic: Medtronic offers deep brain stimulation (DBS) and other neuromodulation therapies for refractory epilepsy. As a large incumbent medical device company, it competes for the same epilepsy treatment budget and physician mindshare, though via implantables rather than consumer wearables.
- Apple: Apple is both EpiWatch's core platform partner (Apple Watch, watchOS, App Store, Family Sharing) and a potential long-term competitor as it expands Apple Watch health features. Its HealthKit and sensor roadmap could either enable or substitute EpiWatch's offering.
Others
- wearablehealthtech: Industry media and ecosystem coverage of the wearable health category. Relevant context for EpiWatch's competitive positioning and patient/caregiver awareness channels, though not a direct comparator or competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
EpiWatch social profiles
Digital presenceEpiWatch compliance and trust
Trust signalCompliance1 record
EpiWatch financial estimates
Financial estimateRevenue estimate
Valuation estimate
EpiWatch leadership team
Management profileNumber of profiles
Profiles3 records
EpiWatch funding detail
Funding detailFunding overview
Funding rounds5 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EpiWatch M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EpiWatch
What does EpiWatch do?
EpiWatch is a prescription-based mobile health application that runs on Apple Watch and iPhone to passively detect tonic-clonic (grand mal) seizures in real time and send alerts with GPS location to designated caregivers. It is the first and only FDA-cleared seizure detection app for Apple Watch, distributed via the Apple App Store on a $19.99/month subscription.
Is EpiWatch a public or private company?
EpiWatch is a private company. It is classified as venture growth investor backed and is currently operating.
When was EpiWatch founded?
EpiWatch was founded in 2015. It employs 1 to 10 people.
Where is EpiWatch based?
EpiWatch is headquartered in Baltimore, United States, in the North America region.
How does EpiWatch make money?
One revenue line is on record: subscription (Apple App Store).
Who are EpiWatch's main competitors?
Direct peers on record are Empatica, Smart Monitor (Inspyre) and Brain Sentinel. Emerging players are Epitel, Seer Medical and Zeto. Broad incumbents are NeuroPace, Medtronic and Apple. wearablehealthtech is listed as an others.
Does EpiWatch have an API?
No public API is recorded for EpiWatch.
What industry is EpiWatch in?
EpiWatch's product category is Digital Health Software. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HSAHAHAI, Wearable Medical Alert Devices (Pendants, Watches, Bands). Its NAICS code is 334510 and its SIC code is 3845.